# James Reinstein

> James Reinstein is the President and CEO of Conformal Medical, a New Hampshire medical device company building next-generation left atrial appendage occlusion (LAAO) technology to reduce stroke risk in patients with atrial fibrillation. A three-decade medtech operator, he spent 17 years at Boston Scientific in commercial leadership across Asia, Europe and Latin America before running a string of device companies as CEO, including Cutera, Drawbridge Health, Aptus Endosystems and Saranas. Known for insisting that a device company think commercially from day one, he took the helm at Conformal in 2022 to guide its foam-based CLAAS system through pivotal trials toward market.

- **Role:** President & CEO at Conformal Medical
- **Organizations:** Conformal Medical, Saranas, Cutera, Drawbridge Health, Aptus Endosystems, Cyberonics, Boston Scientific
- **Nationality:** American
- **Education:** B.B.A., Marketing, University of Georgia, Executive Management training, INSEAD
- **Known for:** Helped grow Cyberonics' market capitalization from roughly $200 million to $3 billion during a turnaround, Led Aptus Endosystems to acquisition by Medtronic, Guided Drawbridge Health to acquisition by Thorne HealthTech

## Career timeline

- **1990** — Joined Boston Scientific, beginning a 17-year run in commercial leadership roles
- **1990s-2007** — Held roles at Boston Scientific including European Head of the Neurovascular Division, Country Director for Mexico, and Vice President / Regional Head for Asia
- **2007** — Left Boston Scientific; later served as Senior VP and Chief Commercial Officer at Cyberonics, helping grow its market cap from ~$200M to ~$3B
- **2010s** — Became CEO of Aptus Endosystems, his first startup role, which was acquired by Medtronic (reported ~$120M)
- **2017** — Named President, CEO and Director of Cutera (NASDAQ: CUTR)
- **2019** — Departed Cutera as President and CEO
- **2019-2021** — Led Drawbridge Health, later acquired by Thorne HealthTech
- **2021** — Served as President, CEO and board member of Saranas Inc.
- **2022** — Appointed President and CEO of Conformal Medical (September 7, 2022), succeeding Andy Levine
- **2024** — Personally contacted all 50 CONFORM trial sites during a study pause; all sites remained enrolled
- **2025** — Conformal Medical raised a Series D financing (latest funding ~$32M, August 2025; total funding ~$161M)

## Achievements

- Helped grow Cyberonics' market capitalization from roughly $200 million to $3 billion during a turnaround
- Led Aptus Endosystems to acquisition by Medtronic
- Guided Drawbridge Health to acquisition by Thorne HealthTech
- Ran commercial operations across Asia, Europe and Latin America over 17 years at Boston Scientific
- Retained all 50 clinical trial sites through the CONFORM study pause by leading transparent, direct communication
- Steered Conformal Medical through multiple financing rounds toward a total of roughly $161 million raised

## Latest updates

- **2025-08** — Conformal Medical secured additional financing (reported latest funding round of roughly $32 million), bringing total funding to about $161 million.
- **2024-01** — Reinstein led direct outreach to all 50 CONFORM trial sites during a study pause, retaining full site participation.

## Links

- Website: https://conformalmedical.com
- LinkedIn: http://www.linkedin.com/in/james-reinstein-7755a634

---

Profile page: https://yespress.io/james-reinstein
Published by YesPress — https://yespress.io
Last updated: 2026-07-16